Orszagos Onkologiai Intezet
- Address
- lock Available on a paid plan
Orszagos Onkologiai Intezet - National Institute of Oncology
The Orszagos Onkologiai Intezet (National Institute of Oncology) is a leading comprehensive cancer research center in Hungary, conducting extensive clinical trials across diverse oncological specialties. The institute demonstrates particular expertise in targeted therapy and immunotherapy trials, with significant involvement in Phase 3 studies evaluating novel therapeutic combinations for solid tumors and hematologic malignancies.
- Advanced breast cancer research including hormone receptor-positive and HER2-positive subtypes, with focus on CDK4/6 inhibitors, antibody-drug conjugates, and combination immunotherapy approaches
- Thoracic oncology including non-small cell lung cancer and small cell lung cancer, investigating targeted agents for KRAS mutations, ALK-positive disease, and immunotherapy-based regimens
- Hematologic malignancies including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and Hodgkin lymphoma with emphasis on BTK inhibitors and bispecific antibodies
- Genitourinary cancers including metastatic castration-resistant prostate cancer, renal cell carcinoma, and urothelial carcinoma utilizing hormonal agents, PARP inhibitors, and antibody-drug conjugates
The institute actively participates in multinational trials for head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, and ovarian cancer, investigating novel combinations of targeted therapies with immunotherapy. The center's research portfolio reflects a commitment to precision oncology and personalized medicine approaches, with particular emphasis on biomarker-directed therapies and innovative drug combinations for treatment-resistant malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 225 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 223 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 33 by active trials.
- 1AstraZeneca AB14active
lock +32 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB34trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Orszagos Onkologiai Intezet
lock Showing 1 of 165 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 225 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 53 | Unknown | 2015-11-06 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.